{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-017209","form_type":"8-K","ticker":"GTBP","cik":"0000109657","company_name":"GT Biopharma, Inc.","filed_at":"2024-04-30T23:59:59+00:00","discovered_at":"2026-05-14T18:03:17.271353+00:00","generated_at":"2026-06-03T03:59:35.712911+00:00","sec_items":["1.01","9.01"],"event_type":"other_material","sentiment":"neutral","materiality_score":0.4,"calibrated_materiality_score":0.4,"confidence":"high","headline":"GT Biopharma amends agreement with Cytovance to raise ownership cap from 4.9% to 9.9%","bullets":["Cytovance's beneficial ownership limit raised from 4.9% to 9.9% of GT Biopharma's outstanding common stock.","Amendment effective April 25, 2024; all other terms of the Aug 24, 2022 Settlement and Investment Agreement unchanged.","Excess shares above 9.9% cap to be issued in quarterly installments with 10-day prior notice from GTBP.","Executed by GTBP Executive Chairman Michael Breen and Cytovance CFO David Knauss."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-017209","json":"https://secwatch.observer/filing/0001493152-24-017209.json","markdown":"https://secwatch.observer/filing/0001493152-24-017209.md","text":"https://secwatch.observer/filing/0001493152-24-017209.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/109657/000149315224017209/0001493152-24-017209-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/109657/000149315224017209/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-03T03:59:35.712911+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[{"claim_id":"19bd887360f82de28e3da5f2f5dda1af55cb238e","claim":"GT Biopharma, Inc. amended Amendment No. 1 to Settlement and Investment Agreement with Cytovance Biologics, Inc. (effective 2024-04-25).","evidence_excerpt":"On April 25, 2024, the Registrant entered into Amendment No. 1 to Settlement and Investment Agreement (the “Amendment”) with Cytovance to increase the limit on Cytovance’s ownership of shares of the Registrant’s common stock from 4.9% to 9.9% of the outstanding shares of the Registrant’s common stock.","evidence_source":"SEC 8-K Item 1.01/1.02","evidence_url":"https://www.sec.gov/Archives/edgar/data/109657/000149315224017209/0001493152-24-017209-index.htm","confidence":0.9,"family_label":"Material Agreements","details":[{"label":"Action","value":"amendment"},{"label":"Agreement","value":"settlement"},{"label":"Counterparty","value":"Cytovance Biologics, Inc."},{"label":"Effective","value":"2024-04-25"}],"fact_type":"material_agreement"}],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}